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Abstract
Introduction. The role of IgA receptors in dermatitis herpetiformis (DH) pathogenesis is still unknown. CD89 
and CD71 may be associated with immune response during DH development. The purpose of this study 
was to perform semiquantitative analysis of simultaneous immunoexpression of CD89 and CD71 in DH and 
IgA/neutrophil-mediated non-DH dermatoses (IgAN) in relation to specific IgA autoantibodies/antibodies (tissue 
and epidermal transglutaminases, nonapeptides of gliadin — eTG/tTG/npG) as well neutrophil activation via 
the release of neutrophil elastase (NE).
Material and methods. In total, 48 patients were studied. The study was conducted on skin lesions and sera 
obtained from DH and IgAN patients. DH and IgAN served as mutually positive control groups. We used im-
munohistochemical technique with semiquantitative digital morphometry and ELISA to measure serum levels 
of anti-eTG/tTG/npG IgA.
Results. CD89 showed a significantly higher expression in DH than in IgAN. CD71 was overexpressed in DH and 
IgAN. CD89 immunoexpression correlated negatively with CD71 in IgAN. A positive correlation was revealed 
between CD89 immunoexpression and anti-npG IgA in DH. No statistically significant correlations were found 
in DH between the CD89/CD71 and NE immunoexpression, between CD71 immunoexpression and anti-tTG/ 
/eTG/npG IgA, or between CD89 immunoexpression and anti-eTG/tTG IgA serum levels.
Conclusions. CD89 is probably a key IgA Fc receptor in DH development, where it is associated with immune response 
to gluten. CD71 may be linked with inflammation in DH and IgAN. We suggest that interaction between CD89 and 
CD71 can modulate the inflammation in IgAN. (Folia Histochemica et Cytobiologica 2017, Vol. 55, No. 4, 212–220)
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Introduction
Dermatitis herpetiformis (DH) belongs to IgA-medi-
ated autoimmune blistering dermatoses. Its etiology 
is multifactorial and still equivocal with involvement 
of both genetic (HLA DQ2/DQ8 haplotypes) and 
environmental factors (gluten intake). Autoimmunity 
as well as inflammation/autoinflammation seem to 
be involved in DH progression [1] since a typical DH 
patient presents circulating IgA autoantibodies/anti-
bodies against transglutaminases (mainly epidermal 
— eTG; tissue — tTG) and nonapeptides of gliadin 
(npG) coupled with rich neutrophilic infiltration 
within the dermal papillae. Activated neutrophils 
may release specific proteolytic enzyme (neutro-
phil elastase, NE) implicated in the destruction of 
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dermal-epidermal junction (DEJ) with the cleavage 
within lamina lucida [2]. 
Direct immunofluorescence of perilesional skin 
revealed pronounced IgA deposits [3, 4], which may 
take various patterns (fine-granular, fibrillar, in 
dermal papillae, along the DEJ, a combination of 
all the above). These deposits are polyclonal, mainly 
composed of IgA1 [5]. 
Hendrix et al. [6] were the first to show the link 
between IgA deposition and recruitment of neutro-
phils in DH and IgA/neutrophil-mediated non-DH 
dermatoses (IgAN). This study also indicated immune 
adherence with Fc receptors engagement as the main 
mechanism of the proposed interaction [6].
Patients with DH have an associated gluten-sensi-
tive enteropathy that is most often asymptomatic [7]. 
However, the development of skin eruption as well as 
cutaneous IgA deposits may be reduced by adhering 
to gluten-free diet.
IgAN are pathogenically closely related to DH 
sharing specific features of skin pathophysiology as 
they exhibit prominent infiltration of neutrophils 
and/or deposition of IgA. IgAN represent a hetero-
geneous group of autoimmune/inflammatory entities 
including linear IgA bullous dermatosis, IgA pemphi-
gus, epidermolysis bullosa acquisita and subcorneal 
pustular dermatosis. 
The formation of IgA (IgA1) deposits contain-
ing immunocomplexes forms a part of not yet fully 
elucidated DH pathogenesis. Although the factors 
that lead to the accumulation of neutrophils in the 
skin are not known, some key molecular factors con-
tributing to the formation of immunocomplexes and 
neutrophilic microabscesses have been proposed. The 
involvement of human IgA Fc receptors, which may 
be associated with neutrophil activation, production 
of autoantibodies as well as gluten transport and/or 
transformation has been suggested in DH. There are 
several known receptors for IgA in humans (e.g. pol-
ymeric Ig receptor, Fc-alpha/microR, CD89, CD71, 
mannose receptor) [8] differing in ligand preference 
and response to IgA binding. 
CD89 (Fc-alphaRI) is a transmembrane glyco-
protein expressed mainly on the surface of cells of 
the myeloid origin binding both IgA1 and IgA2 [9]. 
CD89 shows abundant expression on human neutro-
phils [10, 11] and mediates inflammatory responses 
to IgA-immunocomplexes [8]. CD71, the transferrin 
receptor (TfR), is ubiquitously expressed at low levels 
on normal cells and is expressed at greater levels on 
cells with a high proliferation rate such as cells of 
the basal epidermis and intestinal epithelium [12], 
binding preferentially to polymeric IgA1 [8, 13]. The 
data about the expression of transferrin receptor on 
neutrophils is contradictory; however, specific bind-
ing sites for Tf on the neutrophilic membranes was 
reported [14].
Some researchers showed that CD89 and CD71 
were implicated in the pathogenesis of diseases 
with aberrant IgA synthesis and/or neutrophil tissue 
damage (IgA nephropathy, celiac disease — CD, 
rheumatoid arthritis, systemic lupus erythemato-
sus), where functional abnormalities of CD89 and 
CD71 underlie their onset [8, 14–16]. There are 
data indicating that the formation of IgA-CD89 
may lead to stimulation of CD71 expression [13, 17]. 
However, no attempts have been made to determine 
simultaneous expression of CD71 and CD89 in DH 
patients. Therefore, in the present study we have 
investigated the cutaneous immunoexpression of 
CD89 in concert with CD71 and their relationship 
with the expression of neutrophil elastase as well 
as levels of IgA autoantibodies/antibodies against 
eTG, tTG, npG in the peripheral blood of DH and 
IgAN patients.
Material and methods
This study was conducted after obtaining the local ethical 
committee approval (Poznan University of Medical Sciences, 
953/14, Poznań, Poland, 2014).
Patients and sample collection. Altogether, clinical material 
from 48 patients with autoimmune blistering dermatoses 
before initiation of treatments was obtained. The exam-
ined material consisted of lesional skin tissues and sera 
from the examined groups. Samples were obtained from 
33 patients with DH with active skin rash and 15 IgAN 
patients as a positive control group pathogenetically closely 
related to DH due to ‘neutrophilic endotype’ and/or IgA 
autoantibodies production (involved 9 cases of linear IgA 
bullous dermatosis, 2 cases of IgA pemphigus, 3 cases of 
epidermolysis bullosa acquisita and 1 case of subcorneal 
pustular dermatosis). The DH and IgAN group served as 
mutual control groups. 
To distinguish from DH and establish the diagnoses of 
IgAN, direct immunofluorescence and hematoxylin and 
eosin (H&E) stainings were also done.
Patients were diagnosed and treated as well as samples 
were collected at the Department of Dermatology, Poznan 
University of Medical Sciences, Poland. The diagnosis of DH 
in all DH subjects was established according to: (i) positive 
DIF of perilesional skin (cutaneous IgA deposition in any 
of seven possible diagnostic patterns), (ii) histological fea-
tures of DH (H&E staining), (iii) detection of appropriate 
autoantibodies.
Paraffin-embedded skin tissue 4 μm-thick sections 
were mounted on poly-L-lysine coated glass slides. The 
serum used in the serological tests was taken at the time 
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of hospital admission/ambulatory care. Only patients, 
in whom both tissue sections of an adequate quality for 
processing and serum samples were available for investi-
gation with IHC and ELISA, were subjected to correlation 
studies.
The NE expression was analyzed in the same patients as 
CD89 and CD71 expression. However, the group of patients 
with NE analysis was slightly greater because it was a subject 
of our previous analyses [18–20] which we broadened here 
with the detection of IgA Fc receptors.
Validation of IgA Fc receptors by immunohistochemistry. 
Immunohistochemical (IHC) staining with polyclonal rabbit 
antibodies against human CD89 (anti-CD89, Acris Antibod-
ies GmbH, Herford, Germany), monoclonal murine anti-
bodies against human CD71 (TFRC, Transferrin R antibody, 
Novus Biologicals, Littleton, CO, USA), monoclonal murine 
antibodies against human NE (clone NP57Dako, Glostrup, 
Denmark) and Real EnVision detection kit (Dako) were 
applied according to previously described procedures [19, 
21]. All antibodies were diluted 1:100 in Antibody Diluent 
(Dako). The tests were conducted according to the classi-
cal Peroxidase-DAB staining as described in detail in our 
recent study [21]. 
IgA receptor staining was done after heat-induced 
epitope retrieval in an antigen retrieval solution, high pH 
(Dako). NE staining followed enzymatic digestion of sec-
tions with proteinase K (Dako). 
Internal negative IHC procedure control reactions 
were based on substituting primary antibodies with phos-
phate-buffered saline (Fig. 1). 
Evaluation of the results and microscopy image analysis. 
The slides were examined by light microscopy (BX40, 
Olympus, Tokyo, Japan) connected to a digital camera 
and the images were recorded and archived. The images 
with positive IHC reaction were subjected to semiquanti-
tative morphometric analysis using “HSV Filter” software 
originally developed in the Department of Bioinformatics 
and Computational Biology, Poznan University of Medical 
Sciences, Poland [21–23].
We measured the area of IHC reaction and calculated 
the staining intensity according to the following formula: 
(area of positive IHC reaction/area studied) × 100% [21–23]. 
Then, the mean value was calculated for every patient and 
each studied groups (DH, IgAN).
Immunoenzymatic assay. The concentrations of specific 
circulating serum autoantibodies were detected with com-
mercially available ELISA tests. ELISAs were performed 
using the Euroimmun (Luebeck, Germany) kits to de-
tect IgA autoantibodies/antibodies against (i) the fusion 
protein containing nonapeptides of gliadin (Antigliadin 
GAF-3X IgA ELISA), (ii) tTG (Anti-tTG IgA ELISA). 
The manufacturer-defined cut-off level was 25 RU/ml and 
20 RU/ml, respectively. The level of circulating serum IgA 
autoantibodies against eTG was detected with Anti-eTG 
ELISA (Immundiagnostik AG, Bensheim, Germany) with 
the manufacturer’s cut-off value was 18 AU/ml. 
All measurements were made in ELISA plate reader 
(Expert 96, Asys Hitech GmbH, Eugendorf, Austria) 
equipped with Microwin 2000 software by a single operator 
following the manufacturer’s instructions. 
Statistical analysis. Significant differences in expression 
intensities of CD89/CD71/NE tissue expression were 
done using Wilcoxon signed rank test (comparison within 
examined group) and Mann-Whitney test (comparison 
Figure 1. Negative immunocontrols by omission of the primary antibody (antibodies against either human CD89, CD71 or 
NE were replaced with PBS) for DH patient showing microabscesses of neutrophils at the tips of dermal papillae (arrow) 
with subepidermal cleaves above (A) and for IgAN (a patient with linear IgA bullous dermatosis) showing subepidermal 
blister (arrow) filled with neutrophils within and below the blister cavity (B). Abbreviations: DH — dermatitis herpetiformis; 
IgAN — IgA/neutrophil-mediated non-DH dermatoses. Original magnification 200×.
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between examined groups) with a significance level of p < 
< 0.05. Correlations were calculated using Spearman’s rank 
correlation coefficient. Statistical analyses were performed 
using statistical analysis software Statistica PL 10.0 (StatSoft, 
Cracow, Poland).
Results
Immunoexpression of CD89 and CD71  
in cutaneous lesions of DH and IgAN patients
The results of CD89 and CD71 expression analysis in 
representative DH and IgAN patients are shown on 
Figures 2, 3 and 4. 
The tissue localization of CD89 in the DH involved 
mostly cell nucleus and membranes of neutrophils 
within microabscesses at papillary tips (Fig. 2A and 
3A, B). CD89 expression in IgAN was poorly accented 
(Fig. 2C and 4A, B). CD71 immunoreactivity in DH 
and IgAN was observed frequently in the cytoplasm 
of neutrophils forming inflammatory infiltrates, 
however, the intensity of the reaction was irregular 
(Fig. 2B, D; 3C, D; 4C, D).
Semiquantitative results of CD89, CD71 and NE 
immunoexpression in the examined groups were 
presented in Table 1. The intensity of cutaneous 
CD89 expression, detected in neutrophil-rich in-
flammatory infiltrates at the tips of dermal papillae 
in DH as well as within and below the blister cavity 
in linear IgA bullous dermatitis, was significantly 
increased in DH compared to IgAN (p = 0.0432, 
Mann-Whitney test). No difference in the cutane-
ous immunoexpression of CD71 between examined 
groups was found. The intensity of CD71 immuno-
reactivity was significantly higher as compared with 
CD89 both in DH (p = 0.007, Wilcoxon test) and 
IgAN (p = 0.0008, Wilcoxon test). Significantly low-
er NE than CD71 immunoexpression (p = 0.0251, 
Wilcoxon test) and slightly higher NE than CD89 
immunoexpression (p = 0.0469, Wilcoxon test) were 
observed in DH. 
Figure 2. The cellular localization of CD89 (A, C) and CD71 (B, D) immunoreactivity in a representative DH patient 
(A and B) as well as IgAN patient (C and D). Areas showing the most intense immunoexpression are marked with arrows. 
Abbreviations as in the description of Figure 1. Original magnification 400×.
A B
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No correlation between cutaneous CD89/CD71 
and NE expression was found in DH. The moderate 
negative correlation between cutaneous CD89 immu-
noexpression and cutaneous CD71 immunoexpression 
in IgAN group (r = –0.539, Spearman’s rank coeffi-
cient) was observed.
No immunoreactivity was found when control 
staining procedure was applied (Fig. 1).
Evaluation of IgA FcRs in relation to the presence 
of autoantibodies/antibodies in serum
Detailed analysis of anti-npG, anti-tTG, anti-eTG 
IgA levels obtained with ELISA tests in DH and 
IgAN is presented in Table 2. A positive relationship 
between CD89 expression intensities and the serum 
level of anti-npG IgA (r = 0.664, Spearman’s rank 
coefficient) was revealed in DH. No correlations were 
observed between CD89 expression and anti-eTG, as 
well as anti-tTG IgAserum levels in DH. There was no 
correlation between the intensity of cutaneous CD71 
expression and anti-npG, anti-tTG, anti-eTG IgA 
level in DH. All values of Spearman’s rank coefficient 
between CD89/CD71 expression and IgA autoantibod-
ies/antibodies levels in DH are presented in Table 3.
No correlations were observed between the 
intensity of cutaneous CD89/CD71 expression and 
anti-npG (r = 0.173 and r = 0.018, respectively), 
anti-tTG (r = 0.018 in both cases) IgA level in IgAN. 
Discussion
The major finding of the present study is that cuta-
neous immunoexpression of CD89 was significantly 
increased in patients with active DH compared with 
subjects with IgAN. Thus, it seems that CD89 may be 
associated with the remodeling of dermal-epidermal 
junction in DH. Nonetheless, additional multicenter 
study should be required to confirm the statistical data 
indicating the role of Fc receptors in DH with the use 
of larger number of untreated DH patients. It should 
Figure 3. CD89 (A) and CD71 (C) immunoreactivity in lesional skin in a representative patient with DH who had serum level 
of anti-tTG IgA > 200 RU/ml as determined by ELISA. The intensity of CD89 (B) and CD71 (D) immunoreactivity was 
processed with digital microscopic image analysis as described in Methods. Abbreviations as in the description of Figure 1, 
tTG — tissue transglutaminase. Original magnification 200×.
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Table 1. Semiquantitative assessment of immunoexpression of CD89, CD71 and NE in dermatitis herpetiformis (DH), and 
CD89 and CD71 IgA/neutrophil-mediated non-DH dermatoses (IgAN)
Variable Group Patients’ number Mean ± SD (%) Median (%) Min. (%) Max. (%)
CD89 DH 19 1.73 ± 1.87 1.19 0.00 8.81
IgAN 15 0.87 ± 0.51 0.76 0.17 1.76
CD71 DH 17 8.10 ± 4.44 6.17 3.03 19.72
IgAN 15 12.78 ± 9.45 12.57 1.25 29.60
NE DH 24 3.46 ± 2.31 3.10 0.00 7.97
Skin samples were stained by immunohistochemistry and the percentage of the area of immunoreaction in the analyzed skin lesions was determined 
as described in Methods. NS — statistically non-significant.
be noted that DH is a relatively rare skin disorder [24]. 
Smith et al. [7] found no difference in CD89 expres-
sion between active, ongoing DH, inactive DH and 
normal subjects, whereas active DH patients showed 
enhanced function of CD89 compared with inactive 
DH and healthy population. It may be postulated that 
ligand binding to CD89 is regulated via inside-out 
signaling — thus cytokine stimulation of cells may 
modulate binding capacity in response to intracellular 
signals without affecting receptor expression levels [7]. 
It has been speculated that CD89 may become primed 
— as a result of cytokines’ production — but surface 
receptor expression is not highly augmented [7]. Our 
results demonstrating no relationship between cutane-
Figure 4. CD89 (A) and CD71 (C) deposits detected by immunohistochemistry in lesional skin in representative patients with 
IgAN. The intensity of CD89 (B) and CD71 (D) immunoreactivity was processed with digital microscopic image analysis as 
described in Methods. Abbreviations as in the description of Figure 1. Original magnification 200×.
A B
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ous CD89 and NE expression are consistent with this 
thesis. Thus, possibly, CD89 is not directly involved 
in the activation of neutrophils through their locally 
enhanced expression in DH. 
Our immunophenotypic characteristics of inflam-
matory cells within cutaneous eruption in DH and 
IgAN showed enhanced expression of CD71 in both 
groups of patients. However, the findings demonstrat-
ed different cellular localization of the IgA receptors 
as CD71 immunoreactivity was observed in the cyto-
plasm and CD89 immunoreactivity was associated 
with neutrophils. Previous data [25–28] indicated 
that CD71 is likely to be the most highly expressed 
as an early precursor with decreasing expression in 
maturing forms of the examined cells since strong and 
diffuse cytoplasmic staining for CD71, similarly as in 
neoplastic cells [28] and erythroid precursors [27], was 
reported. This may suggest that the overexpression of 
this protein concurs with the increased expression of 
its cognate receptor.
It has been suggested that IgA/IgA1 binding to 
CD71 can circumvent the barrier effect of IgA and 
promote the entrance of immunogenic peptides into 
the subepithelial tissue. This effect depends on the 
upregulation of CD71 [29]. It has been also suggest-
ed that IgA/IgA1 bound to CD71 may trigger the 
activation of local memory CD4+ T cells and thus 
perpetuate inflammation [30]. Therefore, it cannot be 
excluded that the overexpression of CD71, induced 
in various pathologies, such as anemia or intestinal 
infections [30], in conjunction with other unknown 
factors, might trigger the initial events inducing DH 
lesions in susceptible subjects. Heyman et al. [30] 
showed that protected transport of gliadin peptides 
occurs in active celiac disease patients via a CD71-me-
diated transcytosis of IgA/gliadin peptides immune 
complexes. Thus, perhaps, CD71 may be associated 
with gliadin transport in a similar way in DH.
Interestingly, a significant positive correlation be-
tween cutaneous CD89 expression and anti-npG IgA 
was confirmed here, supporting our previous thesis that 
CD89 may be associated with gluten intolerance in DH 
rather than with enzyme-driven DEJ remodeling [20]. 
On the other hand, some researchers demonstrated 
the association between CD71 and tTG in CD and IgA 
nephropathy [31, 32], but our results do not confirm 
this interaction in DH. Our results about gliadin-CD89 
relationship may be in line with certain data on IgA ne-
phropathy. It is known that the chronic inflammation in 
patients with gluten intolerance may perpetuate the risk 
of kidney diseases [31]. Wijarnpreecha et al. [31] found 
that the risk of kidney diseases was significantly higher 
among patients with CD. It is postulated that gluten 
may exacerbate IgA nephropathy via gliadin-CD89 
interaction. Data regarding CD71 and gluten hyper-
sensitivity indicated that transferrin receptor is overex-
pressed in patients with CD [31], which was consistent 
with our findings in DH patients. CD89 seems not to be 
related with CD71 in DH development. Nonetheless, 
a negative relationship between CD89 and CD71 was 
found in IgAN. Thus, the inhibitory interaction of these 
receptors may be associated with the inflammation 
process in these dermatoses. 
Our findings may help to understand the patho-
physiological mechanism involving IgA Fc receptors 
related to the formation of neutrophilic microabscess-
es and IgA/IgA1 deposition in DH suggesting CD89 
as an important marker for DH, where it is associated 
with immune response to gluten.
Table 2. Analysis of the results obtained with ELISA tests in dermatitis herpetiformis (DH) and IgA/neutrophil-mediated 
non-DH dermatoses (IgAN)
Variable Group Patients’number Mean ± SD [U/ml] Median [U/ml] Min. [U/ml] Max. [U/ml]
Anti-npG IgA DH 25 175.05 ± 185.38 107.55 6.67 644.11
IgAN 11 3.25 ± 6.24 0.47 0 16.13
Anti-tTG 
IgA
DH 33 373.00 ± 436.15 200.00 4.08 1270.92
IgAN 11 4.97 ± 3.40 3.99 1.39 11.48
Anti-eTG IgA DH 25 14.46 ± 8.55 13.85 2.37 34.02
Abbreviations: eTG — epidermal transglutaminase; tTG — tissue transglutaminase; npG — nonapeptides of gliadin.
Table 3. Values of Spearman’s rank coefficient between ex-
pression of CD89, CD71 (% immunoreactive area per area 
of examined skin lesion) and levels of IgA autoantibodies/ 
/antibodies to eTG, tTG, npG in DH
Parameter CD89 CD71
Anti-eTG IgA 0.464 0.300
Anti-tTG IgA 0.359 0.196
Anti-npG IgA 0.664 0.217
Abbreviations: eTG — epidermal transglutaminase; tTG — tissue trans-
glutaminase; npG — nonapeptides of gliadin.
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Our work was limited by the relatively small 
number of DH patients. It was difficult to collect 
samples from patients with active and untreated DH 
for epidemiologic reasons and due to the monocenter 
nature of this study.
This study corroborates the findings of our previo-
us work [19] indicating that there is no close relation-
ship between the activation of neutrophils migrating 
to the skin and production of IgA autoantibodies to 
tTG/eTG sharing immunogenic epitopes in DH. 
In conclusion, we suggest that CD89 seems to be 
a key receptor required for DH development acting 
as neutrophil function modulator. CD71 might be 
associated with inflammation both in DH and IgAN, 
probably due to the loss of protective function of 
IgA. CD71 and CD89 receptors can interact with 
each other to regulate the inflammation process in 
IgAN. CD89 seems to be related with gluten induced 
immune response in DH. Cutaneous CD71 expression 
is not linked with IgA anti-tTG/eTG/npG autoanti-
bodies/antibodies production in DH as well as IgAN. 
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